Nuvation Bio (NUVB) Common Equity (2023 - 2025)
Historic Common Equity for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to $325.9 million.
- Nuvation Bio's Common Equity fell 3517.55% to $325.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $325.9 million, marking a year-over-year decrease of 3517.55%. This contributed to the annual value of $463.8 million for FY2024, which is 2335.63% down from last year.
- According to the latest figures from Q3 2025, Nuvation Bio's Common Equity is $325.9 million, which was down 3517.55% from $372.9 million recorded in Q2 2025.
- Nuvation Bio's 5-year Common Equity high stood at $641.1 million for Q1 2023, and its period low was $257.2 million during Q2 2024.
- Over the past 3 years, Nuvation Bio's median Common Equity value was $502.7 million (recorded in 2024), while the average stood at $492.6 million.
- Its Common Equity has fluctuated over the past 5 years, first tumbled by 5882.49% in 2024, then soared by 4499.11% in 2025.
- Quarter analysis of 3 years shows Nuvation Bio's Common Equity stood at $605.1 million in 2023, then decreased by 23.36% to $463.8 million in 2024, then dropped by 29.73% to $325.9 million in 2025.
- Its Common Equity was $325.9 million in Q3 2025, compared to $372.9 million in Q2 2025 and $419.5 million in Q1 2025.